Mar 2010 abstract: Incidence and management of (Avastin) bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, March 11, 2010

Mar 2010 abstract: Incidence and management of (Avastin) bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma



METHODS: We identified all patients who received bevacizumab off protocol from August 2004-August 2008. We examined their medical records for reports of confirmed GI perforation, associated clinicopathological factors, treatment, and outcomes. RESULTS: Six (4%) of 160 patients with ovarian carcinoma who had been treated with bevacizumab developed GI perforation.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.